Oral vaccination against bovine tuberculosis with Mycobacterium bovis BCG

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 323-331

  Cross, Martin L ^a   Aldwell, Frank ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

BCG vaccine; Bovine tuberculosis; Livestock; Oral vaccination; Wildlife

Indexed keywords

BACTERIAL DNA; BCG VACCINE; GAMMA INTERFERON; HERMES ANTIGEN; L SELECTIN; LIPID;

BCG VACCINATION; CATTLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FERRET; HUMORAL IMMUNITY; MOUSE STRAIN; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; TH1 CELL; TUBERCULOSIS; VIRUS RECOMBINANT; WILDLIFE;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, WILD; BCG VACCINE; CATTLE; TUBERCULOSIS, BOVINE; VACCINATION;

EID: 34250339228     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.323     Document Type: Review

References (57)

1. Orme I. Adaptive immunity to mycobacteria. Curr. Opin. Microbiol. 7(1), 58-61 (2004).
2. McMurray DN. Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis. Scand. J. Infect. Dis. 33(3), 175-178 (2001).
3. Franco-Paredes C, Rouphael N, del Rio C et al. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. Int. J. Infect. Dis. 10(2), 93-102 (2006).
4. Martin C. Tuberculosis vaccines: past, present and future. Curr. Opin. Pulm. Med. 12(3), 186-191 (2006).
5. Orme IM. Current progress in tuberculosis vaccine development. Vaccine 23(17-18), 2105-2108 (2005).
6. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7(3), 135-137 (2001).
7. Ravoglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a world-wide epidemic. JAMA 273, 220-226 (1995).
8. Bannon MJ. BCG and tuberculosis. Arch. Dis. Child. 80(1), 80-83 (1999).
9. Hoft DF, Brown RM, Belshe RB. Mucosal bacille Calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-γ responses. Clin. Infect. Dis. 30(Suppl. 3), S217-S222 (2000). • One of the few accurately documented papers describing the human immune response to oral bacillus Calmette-Guerin (BCG) vaccination.
10. Cosgrove CA, Castello-Branco LR, Hussell T et al. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect. Immun. 74(4), 2449-2452 (2006). • Important proof-of-principle manuscript, highlighting the immune-boosting efficacy of oral BCG delivery to humans using a bacterial strain (BCG Moreau) that is in current licensed use as an oral tuberculosis (TB) vaccine.
11. Haile M, Schroder U, Hamasur B et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22(11-12), 1498-1508 (2004).
12. Griffin JFT. Veterinary tuberculosis vaccine development. Clin. Infect. Dis. 30(Suppl 3), S223-S228 (2000).
13. Suazo FM, Escalera AM, Torres RM. A review of M. bovis BCG protection against TB in cattle and other animal species. Prev. Vet. Med. 58(1-2), 1-13 (2003).
14. Rupprecht CE, Hanlon CA, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev. Biol. (Basel) 119, 173-184 (2004). • Good overview, outlining the factors contributing to success in the oral rabies vaccination program.
15. Brochier B, Aubert MF, Pastoret PP et al. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev. Sci. Tech. 15(3), 947-970 (1996).
16. Qureshi T, Labes RE, Cross ML et al. Partial protection against oral challenge with Mycobacterium bovis in ferrets (Mustela furo) following oral vaccination with BCG. Int. J. Tuberc. Lung Dis. 3(11), 1025-1033 (1999).
17. Olsen AW, Brandt L, Agger EM et al. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand. J. Immunol. 60(3), 273-277 (2004).
18. Lagranderie M, Chavarot P, Balazuc AM et al. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18(13), 1186-1195 (2000).
19. Gunn JS. Mechanisms of bacterial resistance and response to bile. Microbes Infect. 2(8), 907-913 (2000).
20. Skinner MA, Keen DL, Parlane NA et al. Improving protective efficacy of BCG vaccination for wildlife against bovine tuberculosis. Res. Vet. Sci. 78(3), 231-236 (2005).
21. Buddle BM, Aldwell FE, Keen DL et al. Intraduodenal vaccination of brushtail possums with bacille Calmette-Guerin enhances immune responses and protection against Mycobacterium bovis infection. Int. J. Tuberc. Lung Dis. 1(4), 377-383 (1997). •• Cornerstone paper highlighting the potential for BCG to serve as an effective mucosal-site immunogen if bacilli are delivered to sites of intestinal tract immune induction in a viable state.
22. Lagranderie MR, Balazuc AM, Deriaud E et al. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 64(1), 1-9 (1996).
23. Aldwell FE, Tucker IG, de Lisle GW et al. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect. Immun. 71(1), 101-108 (2003). • First published description of lipid-formulated BCG for oral delivery as a vaccine.
24. Aldwell FE, Baird MA, Fitzpatrick CE et al. Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: anatomical sites of bacterial replication and immune activity. Immunol. Cell. Biol. 83(5), 549-553 (2005).
25. Wedlock DN, Aldwell FE, Keen D et al. Oral vaccination of brushtail possums (Trichosurus vulpecula) with BCG: immune responses, persistence of BCG in lymphoid organs and excretion in faeces. NZ Vet. J. 53(5), 301-306 (2005).
26. Aldwell FE, Cross ML, Fitzpatrick CE et al. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine 24(12), 2071-2078 (2006).
27. Aldwell FE, Brandt L, Fitzpatrick C et al. Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis. Infect. Immun. 73(3), 1903-1905 (2005).
28. Aldwell FE, Keen DL, Parlane NA. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine 22(1), 70-76 (2003).
29. Buddle BM, Aldwell FE, Skinner MA et al. Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis. Vaccine 23(27), 3581-3589 (2005).
30. Buddle BM, Aldwell FE, Keen Dl et al. Oral vaccination of brushtail possums with BCG: investigation into factors that may influence vaccine efficacy and determination of duration of protection. NZ Vet. J. 54(5), 224-230 (2006).
31. Doherty TM, Olsen AW, van Pinxteren L et al. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70(6), 3111-3121 (2002).
32. Cross ML, Lambeth MR, Coughlan Y et al. Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: effect of reducing or eliminating BCG load on cell-mediated immunity. Vaccine 25(7), 1297-1303 (2007).
33. Palendira U, Bean AG, Feng CG et al. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect. Immun. 70(3), 1410-1416 (2002). •• Outlines the patterns of lymphocyte integrin expression that may contribute to tissue-infiltrating protective responses following pulmonary infection.
34. Dorer DE, Lambeth MR, Reitinger C et al. Lymphatic tracing of vaccine and T cell responses following oral vaccination with Mycobacterium bovis (BCG). Tissue Antigens 66(5), 491-492 (2005).
35. Dorer DE, Czepluch W, Lambeth MR et al. Lymphatic tracing and T cell responses following oral vaccination with live Mycobacterium bovis (BCG). Cell. Microbiol. 9(2), 544-553 (2007).
36. lo / CD62 Ligandhi population. Infect. Immun. 73(11), 7759-7764 (2005).
37. Corner LA, Norton S, Buddle BM et al. The efficacy of bacille Calmette-Guerin vaccine in wild brushtail possums (Trichosurus vulpecula). Res. Vet. Sci. 73(2), 145-152 (2002). •• Cornerstone manuscript describing the ability of BCG vaccination to reduce disease incidence in a wildlife vector population.
38. Corner LA, Buddle BM, Pfeiffer DU et al. Aerosol vaccination of the brushtail possum (Trichosurus vulpecula) with bacille Calmette-Guerin: the duration of protection. Vet. Microbiol. 81(2), 181-191 (2001).
39. Manabe YC, Scott CP, Bishai WR. Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG. Infect. Immun. 70(3), 1566-1570 (2002).
40. Hotter GS, Wards BJ, Mouat P et al. Transposon mutagenesis of Mb0100 at the ppe1-nrp locus in Mycobacterium bovis disrupts phthiocerol dimycocerosate (PDIM) and glycosylphenol-PDIM biosynthesis, producing an avirulent strain with vaccine properties at least equal to those of M. bovis BCG. J. Bacteriol. 187(7), 2267-2277 (2005).
41. Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J. 26(1), 162-167 (2005).
42. Dietrich J, Weldingh K, Andersen P. Prospects for a novel vaccine against tuberculosis. Vet. Microbiol. 112(2-4), 163-169 (2006).
43. Benevolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C et al. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - a review. Mem. Inst. Oswaldo Cruz. 100(5), 459-465 (2005).
44. Dobakhti F, Rahimi F, Dehpour AR et al. Stabilizing effects of calcium alginate microspheres on Mycobacterium bovis BCG intended for oral vaccination. J. Microencapsul. 23(8), 844-854 (2006).
45. McCluskie MJ, Weeratna RD, Payette PJ et al. The potential of oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 21(1-3), 103-120 (2001).
46. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J. Control Release 114(1), 1-14 (2006).
47. Roy K, Mao HQ, Huang SK et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5(4), 387-391 (1999).
48. Huang J, Garmise RJ, Crowder TM et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23(6), 794-801 (2004).
49. de Lisle GW, Wards BJ, Buddle BM et al. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis (Edinb.) 85(1-2), 73-79 (2005).
50. Flaherty DK, Vesosky B, Beamer GL et al. Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J. Leukoc. Biol. 80(6), 1262-1271 (2006).
51. Southey A, Sleeman DP, Lloyd K et al. Immunological responses of Eurasian badgers (Meles meles) vaccinated with Mycobacterium bovis BCG (bacillus Calmette Guerin). Vet. Immunol. Immunopathol. 79(3-4), 197-207 (2001).
52. Lesellier S, Palmer S, Dalley DJ et al. The safety and immunogenicity of bacillus Calmette-Guerin (BCG) vaccine in European badgers (Meles meles). Vet. Immunol. Immunopathol. 112(1-2), 24-37 (2006).
53. Aldwell FE, Keen DL, Stent VC et al. Route of BCG administration in possums affects protection against bovine tuberculosis. NZ Vet. J. 43(7), 356-359 (1995).
54. Statens Serum Institut. Human BCG vaccine, summary of product characteristics (online publication) (1993) www.ssi.dk/sw10375.asp
55. Lesellier S, Corner LA, Chambers MA et al. Oral vaccination of badgers (Meles meles) against tuberculosis: immune responses and protection following BCG delivery via the oral route and pulmonary challenge with Mycobacterium bovis. In: Proceedings of the Wildlife Disease Association 55th Annual Meeting. Wildlife Disease Association online publication (2006) www.wildlifedisease.org/Documents/Proceedings/Storrs_06.pdf
56. Nol P, Palmer MV, Waters WR et al. Oral bacille Calmette-Guerin (BCG) vaccination of white-tailed deer against bovine tuberculosis. In: Proceedings of the Michigan Bovine Tuberculosis 11th Annual Meeting. United States Department of Agriculture, Agricultural Research Service online publication (2006) www.ars.usda.gov/research/publications/publications.htm? SEQ_NO_115=196986
57. de Klerk-Lorist LM. The evaluation of a BCG vaccine against bovine tuberculosis in African buffaloes (Syncerus caffir). Electronically published MSc thesis, University of Pretoria, South Africa, online publication http://upetd.up.ac.za/thesis/available/etd-03082005-105106/unrestricted/ 00disserta tion.pdf